Inogen (INGN): Needs to Take a Breath

Citron puts generous target of $95

In the past, Citron has been negative on names as a result of momentum, valuation, or competition.  It is rare that we get an opportunity of the type we currently see in Inogen.  While Wall Street was busy looking at the growth of this high-flying med-tech company, no one looked under the hood to find a future that is guaranteed to have price compression and competition.

Whether you are a Laurel or a Yanny, you cannot fail to hear that Inogen should quickly fall 50%.

Read the full report here